Audentes therapeutics, inc. (BOLD)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14
Operating expenses:
Research and development

104,370

75,902

48,770

20,235

9,280

General and administrative

30,002

17,275

11,276

6,491

1,670

Total operating expenses

134,372

93,177

60,046

26,726

10,950

Loss from operations

-134,372

-93,177

-60,046

-26,726

-10,950

Interest income, net

6,030

767

472

245

6

Other expense, net

-479

-74

-94

23

125

Loss before income taxes

-128,821

-92,484

-59,668

-26,458

-

Income tax benefit

-

-2,246

-

-

-

Net Income (Loss) Attributable to Parent

-128,821

-90,238

-59,668

-26,458

-10,819

Unrealized losses on short-term investments

-60

-51

-19

-

-

Unrealized (losses) gains on investments, net

-

-

-

-

-10

Comprehensive loss

-128,881

-90,289

-59,687

-26,458

-10,829

Net loss per share, basic and diluted (USD per share)

-3.40

-3.40

-5.59

-23.03

-21.56

Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)

37,839

26,578

10,673

1,148

501